Evidence map›Paper›PMID 29371883›Full record

ArticleBiotechnology for biofuels2018

Conversion of lignocellulosic agave residues into liquid biofuels using an AFEX™-based biorefinery.

Carlos A Flores-Gómez, Eleazar M Escamilla Silva, Cheng Zhong, Bruce E Dale, Leonardo da Costa Sousa, Venkatesh Balan

Abstract read
In one paragraph

Article in Biotechnology for biofuels, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. The complete chloroplast genome ofMitochondrial DNA. Part B, Resources · 2021
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Carlos A Flores-Gómez1Departament of Chemical Engineering, Tecnológico Nacional de México, I. T. Celaya, Av. Tecnológico S/N, 38010 Celaya, Guanajuato Mexico.ORCID 0000-0002-9530-4685
Eleazar M Escamilla Silva1Departament of Chemical Engineering, Tecnológico Nacional de México, I. T. Celaya, Av. Tecnológico S/N, 38010 Celaya, Guanajuato Mexico.
Cheng Zhong5Key Lab of Industrial Fermentation Microbiology of Ministry of Education, School of Biotechnology, Tianjin University of Science & Technology, Tianjin, People's Republic of China.
Bruce E Dale2Department of Chemical Engineering and Materials Science, Michigan State University, 3815 Technology Boulevard, Lansing, MI 48910 USA.
Leonardo da Costa Sousa2Department of Chemical Engineering and Materials Science, Michigan State University, 3815 Technology Boulevard, Lansing, MI 48910 USA.
Venkatesh Balan2Department of Chemical Engineering and Materials Science, Michigan State University, 3815 Technology Boulevard, Lansing, MI 48910 USA.ORCID 0000-0003-3109-5156

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAgave-based alcoholic beverage companies generate thousands of tons of solid residues per year in Mexico. These agave residues might be used for biofuel production due to their abundance and favorable sustainability characteristics. In this work, agave leaf and bagasse residues from species

resultsLow-severity AFEX pretreatment conditions are required (100-120 °C) to enable efficient enzymatic deconstruction of the agave cell wall. These studies showed that AFEX-pretreated

conclusionsThese results show that AFEX-pretreated agave residues can be effectively hydrolyzed at high solids loading using an optimized commercial enzyme cocktail (at 25 mg protein/g glucan) producing > 85% sugar conversions and over 40 g/L bioethanol titers. These results show that AFEX technology has considerable potential to convert lignocellulosic agave residues to bio-based fuels and chemicals in a biorefinery.

Indexed as

AFEXAgaveBiofuelBiomassCellulaseEnzymatic hydrolysisEthanolFermentationLignocellulosicPretreatment

Identifiers

PMID29371883
PMCPMC5769373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.